The present invention relates to a cyclic polysaccharide compound and particle comprising a plurality of said cyclic polysaccharide compounds and one or more agent, wherein the plurality of cyclic polysaccharide compounds form a hollow sphere, and the one or more agent is encapsulated within the hollow sphere; and wherein the one or more agent is non-covalently associated with the cyclic polysaccharide compound, optionally further comprising a surfactant. The particles may comprise one or more additional drug. The invention further relates to pharmaceutical, cosmetic, or nutraceutical use of the particles.

The present invention relates to a cyclic polysaccharide compound and particle comprising a plurality of said cyclic polysaccharide compounds and one or more agent, wherein the plurality of cyclic polysaccharide compounds form a hollow sphere, and the one or more agent is encapsulated within the hollow sphere; and wherein the one or more agent is non-covalently associated with the cyclic polysaccharide compound, optionally further comprising a surfactant. The particles may comprise one or more additional drug. The invention further relates to pharmaceutical, cosmetic, or nutraceutical use of the particles.

The present invention relates to modified, improved processes for the preparation of sodium glucose co-transporter 2 (SGLT-2) inhibitors and intermediates thereof. More particularly, the present invention relates to improved processes for the preparation of gliflozin compounds such as empagliflozin and dapagliflozin, intermediates thereof. The product obtained from the processes of present invention may be amorphous or crystalline. Also, the products obtained from the present invention may be used for the preparation of medicaments for the prevention and/or treatment of diseases and conditions associated with SGLT-2 inhibition.

The present invention relates generally to the field of glycanics and its application to the generation of glycoconjugates for therapeutic use. The present invention also relates to process for the preparation of glycoconjugates.

The invention provides a process for preparing sphingolipids, compositions comprising sphingolipids and further components, and for the use of the compositions.

The invention provides a process for preparing sphingolipids, compositions comprising sphingolipids and further components, and for the use of the compositions.

The invention related to organic and bioorganic combinatorial chemistry, namely, to new combinatorial libraries of polysaccharide derivatives and supramolecular structures based on them, which, when used without separation into separate components, have high biological activity.

The essence is a combinatorial library and a supramolecular structure based on it from biologically active derivatives of polysaccharides, as well as pharmaceutical compositions based on them with a hemostatic, wound healing, antiviral and immunomodulating action, containing as an active substance an undivided whole combinatorial mixture of substituted glucopyranose polymer derivatives, obtained simultaneous combinatorial modification of a polysaccharide with at least two covalent modifier in the synthesis, a combinatorial mixture with the maximum number of combinations of modified polysaccharide derivatives is formed, and as a biologically active substance, a whole combinatorial mixture of polysaccharide derivatives in the form of a supramolecular structure without separation into individual components is used to obtain a pharmaceutical composition.

The present disclosure relates to processes for preparing functionalized cyclooctenes and the synthetic intermediates prepared thereby.

Phenol derivatives of general formula (I) and (II), wherein meanings of the substituents are indicated in the description, their pharmaceutically acceptable salts, together with the processes for their preparation, their use as antimicrobial, antibacterial, bactericide agents and the corresponding pharmaceutical compositions are disclosed.

The disclosure relates to GalNAc moieties comprising at least one GalNAc monomer. The disclosure also relates to GalNAc-oligonucleotide conjugates comprising GalNAc moieties and oligonucleotides, e.g., saRNAs or siRNAs useful in regulating the expression of a target gene. Methods of using the GalNAc-oligonucleotide conjugates are also provided.